5-bromodeoxyuridine (BrdU) labeling was employed to explore the effects of methylmercury (MeHg) on cell cycle kinetics in the developing rat midbrain during gestational days (GDs) 11 to 14. Contrary to what has been previously reported in mice, no effects of MeHg on cell cycle kinetics were observed up to embryonic brain concentrations of 3-4 g/g. The absence of an effect was confirmed using stereology and counts of midbrain cell number. Treatment with colchicine, the positive control, resulted in significant effects on cell cycle kinetics in the developing rat midbrain. The parallelogram method, borrowed from genetic toxicology, was subsequently used to place the data obtained in the present study in the context of previously collected in vitro and in vivo data on MeHg developmental neurotoxicity. This required developing a common dose metric (g Hg/g cellular material) to allow in vitro and in vivo study comparisons. Evaluation suggested that MeHg's effects on neuronal cell proliferation show a reasonable degree of concordance across mice, rats, and humans, spanning approximately an order of magnitude. Comparisons among the in vivo data suggest that humans are at least or more sensitive than the rodent and that mice may be a slightly better model for MeHg human developmental neurotoxicity than the rat. Such comparisons can provide both a quantitative and a qualitative framework for utilizing both in vivo and in vitro data in human health risk assessment.
Cell production in the developing embryo and fetus is a highly regulated and coordinated activity, with waves of cell division, migration, and differentiation occurring in different brain regions at different times (Rodier, 1995) . Disruption of these processes, particularly cell proliferation, is a common feature of many neurodevelopmental toxicants. Environmental agents that alter cell proliferation include rubella, ionizing radiation, cancer chemotherapeutic or antiviral therapy, and exposure to agricultural fungicides or metals (Scott, 1977) . Experimental evidence supports the theory that cell cycle inhibition caused by environmental agents can produce regionally defined alterations in nervous system morphology, and the resultant neuropathological effects can be linked with specific neurobehavioral deficits (Rodier, 1983; Rodier et al., 1984) . For example, in utero exposure to valproic acid and thalidomide at clearly defined time points has been linked with autism (Rodier et al., 1996) . In these studies, neuropathological examination revealed a loss of specific nuclei in the hindbrain, specifically the superior olive and facial nuclei (Rodier et al., 1996) . However, in most cases, it is not possible to correlate altered neurobehavior with central nervous system (CNS) pathology, particularly if exposure causes subtle effects on cell number, migration, orientation, or synaptogenesis. In cases where subtle changes in cell-specific population abundance and distributions are suspected, quantitative stereology can be applied to examine changes in cell number and distribution.
The developing nervous system is highly susceptible to the toxic effects of methylmercury (MeHg). The effects of in utero exposure include both sensory and motor disturbances, with more severe exposures producing mental retardation (Burbacher et al., 1990) . Pathology studies of human infants and animals exposed to MeHg during gestation demonstrate alterations in cell number, brain size, cell orientation, and distribution (Chen et al., 1979; Choi et al., 1978; Eto et al., 1992; Rodier et al., 1984) . Burbacher et al. (1990) noted that cell loss and reduced brain size are consistently observed effects of MeHg exposure across species, from high-dose examples in humans (i.e., Minimata, Iraq) to low-dose examples in rodents (primarily mice). Several studies have indicated that the decreased number of brain cells is a result of the inhibition of proliferation rather than cell death, because decreased proliferation is observed at doses below those that result in cytolethality (Ponce et al., 1994; Sager et al., 1984) . MeHg-mediated mitotic arrest has been observed in vivo (Choi, 1991; Choi et al., 1978; Rodier et al., 1984) and in vitro (Miura et al., 1978;  1 To whom correspondence should be addressed at 4225 Roosevelt Way NE, Suite 100, . E-mail: faustman@ u.washington.edu. Ponce et al., 1994; Sager, 1988; Vogel et al., 1986) . Disruption of microtubule formation, oxidative stress, altered cellular signaling, gene expression, and protein phosphorlylation have been reported at low MeHg exposure concentrations, i.e., 1 M or lower (Minnema et al., 1989; Miura et al., 1984; Rajanna et al., 1995; Sarafian and Verity, 1991; Vogel et al., 1985; Zucker et al., 1990) . Such effects may contribute independently or jointly to the observed effects of MeHg on mitotic progression. Ponce et al. (1994) studied the effects of MeHg exposure on micromass cells, that is, primary rat midbrain cells dissociated and cultured at a high density. Via flow cytometry, they observed a clear G2/M phase arrest in cells exposed to 2 to 4 M of MeHg, which is similar to the type of cell cycle arrest that is observed when cells are exposed to the mitotic spindledisrupting drug colchicine. These results, in a primary, nonimmortalized CNS culture, are consistent with similar effects observed in other cell culture systems (Miura et al., 1984; Vogel et al., 1986; Wasteneys et al., 1988; Zucker et al., 1990) as well as in vivo in mice Sager et al., 1984) .
The aim of the investigation reported here was to observe the effects of MeHg on cell proliferation in rat midbrain cells in vivo using flow cytometry and quantitative stereology. These observations would provide an in vivo extension of our previous rat in vitro studies (Ponce et al., 1984) . A second goal was to develop a quantitative framework that would allow for consideration and comparison of in vitro and in vivo midbrain data. In particular, we were interested not only in the differences in mouse versus rat data, but also in the differences in each species between in vitro and in vivo assessments. These comparisons would provide some indication of the similarity in quantitative response between the in vivo and in vitro systems. Our hypothesis was that, at doses similar to those used in the in vivo mouse studies (i.e., 1-2 g/g in the embryonic brain), cell cycle disruption would be observed in the rat.
MATERIALS AND METHODS

Experiment 1: Cell Cycle Kinetic Studies
The design of the in vivo studies used to examine the cell cycle effects of MeHg are summarized in Table 1 .
Animals. Time-mated female Sprague-Dawley rats were obtained from Charles River Laboratories (Hollister, CA). The morning after mating was designated GD 0. The animals were shipped from the breeding facility to the University of Washington Health Sciences Complex on GD 6. They were kept on a 12-h light/dark cycle, fed with standard rat chow, and watered ad libitum. Animal care and treatment followed a university-approved animal use protocol developed in accordance with NIH guidelines.
Treatment. The animals were dosed subcutaneously (sc) with MeHgOH (Alpha Aesar, Ward Hill, MA) in the afternoon of GD 11. The control animals received sc doses of sterile saline. Total maternal MeHg doses ranged from 5 to 20 mg/kg. Toxicokinetic data (Lewandowski et al., 2002) indicated that mercury (Hg) concentration in the embryos approached maximum levels 24 h after dosing. Twenty-four or 48 h after MeHg dosing (GD 12, Witschi stage 21; GD 13, Witschi stage 27), short-term (1.5-h) bromodeoxyuridine (BrdU) exposures were carried out. The animals received a single intraperitoneal (ip) injection of BrdU (18 mg/ml dissolved in phosphate-buffered saline (PBS), pH 7.7, total dose ϭ 25 mg/kg) and were sacrificed 1.5 h later. After sacrifice, tissues were collected and processed as described below. A second set of experiments was carried out using 6-h BrdU exposures because previous studies (Miller and Nowakowski, 1991; Miller et al., 1995) indicate that changes in the fraction of BrdU-labeled cells may be easier to detect with longer labeling times. In these experiments, the animals were dosed with MeHg on GD 11, received an injection of BrdU at 8:00 A.M. on GD 12, and received a second injection 5 h later (1:00 P.M.). The animals were sacrificed approximately 1 h later (total labeling time, 6 h). Previous work indicated that the average duration of the S-phase in these cells was approximately 8 h (Lewandowski et al., 2003) . Thus an interval of 5 h between BrdU injections was sufficient to label all cycling cells (i.e., with BrdU administration every 5 h, no cells would pass completely through the S-phase without being exposed to BrdU). To provide a positive control for MeHg treatment, several animals were also treated with colchicine, a known mitotic spindle inhibitor. Dams were dosed intraperitoneally (ip) with 0.7 or 1.0 mg/kg colchicine (three dams per treatment group) on the morning of GD 12, approximately 30 min prior to the start of BrdU administration. Dosing with colchicine (Sigma-Aldrich, St. Louis, MO) was conducted on GD 12 due to the short half-life of colchicine, reported to be 16 min in the rat (Leighton et al., 1990) . Dosing one day prior Tissue collection. At the appropriate time interval after BrdU injection, the animals were killed using CO 2 . The uteri were removed, placed on ice, and maintained cold while the embryos were dissected out of the uterine tissues. Dissection on ice has been used to halt BrdU incorporation in embryonic tissues (Miller and Kuhn, 1995) and allows for control of the time of BrdU exposure. After the embryos were obtained from the uteri, the developmental stage was confirmed by measuring the crown rump length, counting somites, and evaluating the overall morphology and comparing these to a standard reference (Altman and Bayer, 1995) . The embryos were examined for gross pathologies (i.e., smaller size or abnormal morphology relative to controls) when removed from the uterine tissue. The embryonic midbrains were then sectioned from the body of the embryo. All of the midbrains obtained from each litter were pooled and dissagregated using 0.25% trypsin/2.5% collagenase and trituration (25°C). The midbrain cell suspensions were then washed with PBS/5% normal goat serum (NGS), and the cells were fixed in cold 70% ethanol (4°C). All work was conducted using dark room lights to minimize BrdU photoactivation.
The embryonic bodies were frozen at -80°C and later analyzed for total Hg content according to the methods described in Lewandowski et al. (2002) . The toxicokinetic data (Lewandowski et al., 2002) indicated that, at this gestational period, embryonic body Hg concentration serves as a reasonable indicator of Hg content in the embryonic brain.
Cell staining. The cells were centrifuged (10 min, 700 r.p.m., 25°C for all spins) in 70% ethanol and then resuspended in 1 ml PBS/5% NGS. The cells were allowed to rehydrate at room temperature overnight, as this was found to provide better antibody access to DNA. After the overnight rehydration, the cells were centrifuged and resuspended in 150 l of PBS/NGS and 450 l of membrane-shredding solution [100 ml calcium magnesium free (CMF)-PBS, 500 l NP-40, 20 mg ethylenediamine tetracetic acid (EDTA)]. The samples were placed on ice and vortexed vigorously every 3 min for 20 min to disrupt the cells and gain access to the ethanol-fixed nuclei. The samples were then acidified with 800 l of 4N HCl and agitated for 45 min at room temperature to denature the double-stranded DNA and allow antibody access. The nuclei were then washed twice with 3 ml 1-M Tris (pH 8.5) and counted using a hemocytometer. The samples were then completely decanted and resuspended with fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody (Pharmingen, San Diego, CA) at a ratio of 150 l antibody to 1E6 cells. The antibody was previously diluted to 1:20 with PBS/NGS/0.5% Tween 20. After 1 h of incubation at 25°C, the samples were washed once with PBS/NGS and resuspended in PBS for flow analysis. Immediately prior to flow analysis, propidium iodide (PI), a DNA staining dye, was added to achieve a final PI concentration of 5 g/ml in the sample.
Flow cytometry. Flow cytometry was used to determine the fraction of cells positively labeled with BrdU and the cell cycle profile (i.e., %G1, %G2, and %S). Dual-parameter flow cytometry utilized a Coulter EPICS Elite equipped with a coherent Innova 90 air-cooled argon laser. Excitation occurred at 488 nm for both the FITC and PI. Fluorescence measurements were obtained from approximately 20,000 cells. The data were analyzed using the software package Mplus (Phoenix Flow Systems, San Diego, CA).
Cell cycle kinetic parameter estimation. The S-phase length (Ts) was determined from the pulse-labeling study by the shift in mean PI fluorescence of the BrdU-labeled cells after 1.5 h of BrdU exposure using the method of Begg et al. (1985) as modified by Terry et al. (1991) . The fractions of labeled cells at 1.5 and 6 h of BrdU exposure were determined with adjustments for cells that divided during the labeling period (Nowakowski et al., 1989) .
The effect of embryonic Hg concentration on the cell cycle parameters was evaluated using linear regression and a significance criterion of 0.05. In the case of the 6 h BrdU exposures, the data were also grouped by concentration and analyzed using a t-test or ANOVA.
Experiment 2: Stereology Studies
The design of in vivo stereology studies used to confirm the cell cycle results is summarized in Table 2 .
Dosing and embryo isolation. To obtain confirmatory data for the cell cycle kinetic studies, four embryos each from two MeHg-treated dams were also obtained for stereological evaluation of the midbrain cell number. The dams were dosed sc with 18 mg/kg MeHg on GD 11 (i.e., the same time as dosing in the cell cycle studies). Embryos were obtained on GD 14 using the procedures described above (i.e., one day later than in the cell cycle studies). One-half of the embryos (one side of the horn) were used for counting while the other half were used for mercury analysis. Mercury analysis was performed on the whole embryonic body, which we have previously shown is a reasonable surrogate for midbrain mercury concentration at this gestational age (Lewandowski et al., 2002) . Each embryo used for counting was assigned a specific code number so that counting was performed with the observer blind to uterine position and treatment status.
Tissue preparation. Following fixation by whole-body immersion in 4% paraformaldehyde (carried in 0.1-N dibasic sodium phosphate buffer, pH 7.2), whole bodies or heads of embryos (depending on age/size) were specifically positioned by embedment in a 3% agar matrix to facilitate handling during subsequent tissue processing and increase histology efficiency by allowing entire sets of embryos to be processed together as a single tissue set. The agar blocks containing the tissue were dehydrated in a graded ethanol series and embedded in glycomethacrylate (Historesin, Cambridge Instruments, Deerfield, IL). The blocks were exhaustively sectioned in the sagittal plane at a thickness of 20 or 30 m on a JB-4 microtome (Sorvall) using glass knives, and all sections were collected in the order generated. The sections were stained with Giemsa (stock solution, J. T. Baker, Phillipsburg, NJ) using the procedure of Iñiguez et al. (1985) and following the suggestions of Braendgaard et al. (1986 Braendgaard et al. ( , 1990 .
Stereology. Estimates of the number of neurons in the developing rat midbrain were determined by use of the Optical Volume Fractionator (OVF) procedure of Bolender and Charleston (1993) as previously described in Charleston (2000) . A detailed explanation of this methodology is provided in Lewandowski et al. (2003) .
Counting was performed on every twelfth section in the set of sections, and 100 to 300 neuroepithelial cells were counted per individual. The boundaries of the midbrain were determined by use of a developmental rat atlas (Altman and Bayer, 1995) . The areas considered for cell enumeration included the developing region of the thalamus, thus enabling use of the unambiguous boundary formed by the prominent fissure separating the thalamus from the Note. NA, not applicable. a Cell cycle kinetics evaluations were performed on a litter-by-litter basis using pooled embryos.
b Previously reported in Lewandowski et al. (2003) .
cerebral cortex. Otherwise, determination of the boundary between the midbrain and the thalamus would have required the use of arbitrary boundaries, resulting in equally arbitrary estimates of the total number of neuroepithelial cells. This area of interest was identified by extending a line between the base of the cerebellar sulcus and the base of the thalamus, thereby transecting the ventricular space (Fig. 1 ). This approach was consistent with the cell cycling studies in that the same brain region was evaluated in both sets of experiments. The treated embryo results were compared to the embryonic midbrain counts determined from GD 11 to GD 16, which we have published previously (Lewandowski et al., 2003) .
Experiment 3: Evaluation of Hg Concentrations in Vitro
To permit comparison of previous in vitro data with results of our in vivo study described above, a common dose metric was required. In vitro studies generally report chemical exposures as media concentrations (e.g., M), whereas in vivo studies typically report tissue concentrations (e.g., g/g). To establish a means of comparison, micromass (primary embryonic rat midbrain) and P19 cells (murine embryonic carcinoma cells) were used to measure the mercury uptake from the culture media. For micromass cultures, the culture medium was Hams's F12 supplemented with 10% fetal bovine serum, penicillin (50 IU/ml), streptomycin (5 g/ml), and L-glutamine (5.8 mg/ml). For P19 cultures, the medium was the same, except that F12 was replaced with Dulbecco's Modified Eagle Medium (DMEM). The cultures were grown on Falcon Primaria dishes (Beckton-Dickinson Labware, Lincoln Park, NJ) possessing a hydrophillic polystyrene culture surface. The cells were incubated at 37°C in a 5% CO 2 /95% air atmosphere with 100% relative humidity for 2 h to allow for attachment prior to treatment. The media was then removed and replaced with an MeHg-containing media (0.5, 1.0, and 2.0 M), and the cells were further incubated for 6 h. This was believed to be sufficient time for the MeHg to equilibrate between the cells and the media (Furukawa et al., 1982) . After treatment, the culture medium was removed and the cells were rinsed twice with CMF-PBS. The cells were then incubated for 5 min at 37°C in 500-l CMF-PBS containing 0.05% trypsin and 0.02% ETDA. Following incubation, 500 l of mercury-free culture medium was added to each dish, and the cells were collected into 15-ml polystyrene centrifuge tubes. The cells were centrifuged at 800 r.p.m. for 20 min at 4°C, the supernatant was decanted, and the cells were stored at -80°C until analyzed for mercury. Approximately 0.15 g of the cellular material was collected per experiment. One to two experiments were conducted at each dose level/cell type. Analysis for total cellular Hg was conducted using an atomic fluorescence spectrometer (PSA Ltd., Kent, UK), as described in Lewandowski et al. (2002) . The media concentrations were identical to those used by Ponce et al. (1994) , and the cell culture methods were similar to those employed in that study. During collection, the cell suspensions were washed several times to remove any extracellular Hg that might have been present in the media or loosely associated with the cell membranes. A linear regression was used to determine the relationship between the intracellular Hg content and the Hg in the culture media.
RESULTS
No overt signs of toxicity were observed in the maternal animals treated with MeHg or colchicine. The MeHg-or colchicine-treated embryos were observed morphologically under ϫ10 magnification, and no differences in viability, size, or gross morphology were noted relative to the controls. The mercury tissue concentrations for all MeHg-treated animals are provided in Table 3 . . The cell cycle distribution (percent G1, S, and G2/M) was also not significantly different for MeHg-treated animals (data not shown). 
Six-h BrdU labeling. The results for the 6-h BrdU exposures subsequent to
FIG. 3.
Effect of methylmercury treatment on the S-phase length in midbrain cells. The embryos were exposed to BrdU through maternal ip dosing and sacrificed 90 min later. The S-phase length was estimated using the relative movement approach of Begg et al. (1985) . The data were analyzed using linear regression. Neither the 24-nor 48-h exposures resulted in statistically significant effects on the S-phase duration. Each point shown represents a result for an individual pooled litter.
FIG. 4.
Effect of methylmercury treatment on cell cycling in rat midbrain cells after 6 h of BrdU exposure. The embryos were exposed to BrdU through maternal ip dosing and sacrificed 6 h later. The MeHg data shown are those for four litters with a mean Hg concentration of 2.5 g/g (SD ϭ 0.1 g/g). There were also four litters in the control group. The data were analyzed by t-test. Aside from a marginal significance for new G1 cells (p ϭ 0.05), no other parameters were significantly altered by MeHg treatment.
bryos (64% Ϯ 4%) was not statistically different from the controls (66.9% Ϯ 5%) (t-test, p ϭ 0.29). There was a marginally significant decrease in the new G1 cell population in the MeHg-treated animals (t-test, p ϭ 0.05, regression p ϭ 0.12), but this was likely due to the small variance in the treated animals (coefficient of variation ϭ 1.4%) and not to substantial differences in the means. MeHg treatment did not have any significant effects on cell cycle distribution (t-test and linear regression, p Ͼ 0.1). MeHg therefore did not appear to have any effects on cell cycling in vivo up to an embryonic Hg dose of 2.5 g/g.
The results for in vivo treatment with colchicine, the positive control, are shown in Figure 5 . Colchicine treatment had a clear and highly significant impact on cell cycling. For example, the fraction of BrdU-positive new G1 cells decreased in a dosedependent manner from 23% in the controls to 4% at 0.7 mg/kg and 0.3% at 1 mg/kg (ANOVA, p Ͻ 0.01). A similar effect was seen in the overall fraction of BrdU-positive cells (ANOVA, p Ͻ 0.01). Regarding cell cycle distribution, the percentage of cells in the G2/M and S-phases was increased at the expense of the G1 population, which is consistent with the idea that colchicine causes cell cycle arrest at the point of cell division.
Experiment 2: Stereology Studies
The results of the stereological evaluation are shown in Figure 6 . MeHg treatment of dams, resulting in an embryonic brain mercury level of 2.8 g/g did not have any apparent effects on the cell number 72 h after dose administration. As is shown in Figure 6 , the midbrain cell numbers in MeHg-treated embryos are consistent with the overall developmental growth patterns observed in untreated embryos from GD 11 to GD 16. We also conducted an analysis using a random effects model to determine how large a change in cell number in the MeHg- The dams were then treated with BrdU (ip dosing, 25 mg/kg) and sacrificed 6 h later. Each treatment group shown represents three litters. The data were analyzed using ANOVA. The effect of colchicine on the fraction of BrdU-positive and new G1 cells was statistically significant in a dose-dependent manner (**p Ͻ 0.01). When the two treatment groups were combined, there was also a significant effect on the cell cycle distribution (G2/M and G1, *p Ͻ 0.05; S **p Ͻ 0.10). There were three dams/litters per colchicine treatment group and four dams/litters in the control group.
FIG. 6. Count data for midbrain neuroepithelial cells in control and
MeHg-treated embryos. Each vertical column of data points represents data from an individual litter. The control data were obtained from untreated animals on GD 11 through GD 16 (Lewandowski et al., 2003) . For MeHg treatments (data shown as open triangle; four embryos per litter), the dams were given subcutaneous injections of 18-mg/kg MeHg on GD 11 with embryos obtained and fixed on GD 14. The mean embryonic Hg concentration on GD 14 was 2.7 g/g (litter 1) and 2.9 g/g (litter 2). exposed litters would have been needed to detect a statistically significant difference. We found that an approximately 20% decrease would have been needed to detect a significant effect using our study design.
The data shown in Figure 6 are consistent with the results of the cell cycle kinetic studies described above. An evaluation of the cell number in the treated animals by position on the uterine horn did not indicate selective toxicity to individual embryos, which might have been missed when the animals were considered as a group (data not shown).
Experiment 3: Evaluation of Hg Concentrations in Vitro
The results for the analysis of Hg content in cells exposed in vitro to MeHg are shown in Figure 7 . The increase in cellular Hg concentration was linear across the range tested (i.e., 0.5-2 M). The relationship between the intracellular Hg (g/g) and the culture media Hg (M) was approximately 3 to 1 (r 2 ϭ 0.99), indicating that a media concentration of 1 M of MeHg results in a cellular concentration of 3 g Hg/g tissue. A very similar relationship was observed using P19 cells.
DISCUSSION
In this paper we explored the effects of MeHg on cell proliferation in the developing rat midbrain. Our in vivo data on cell cycle kinetics and the stereological estimates of midbrain cell numbers both indicated no effect of MeHg on midbrain cell cycle kinetics or cell numbers at embryonic Hg concentrations up to 2.5 g/g. Previous studies in mice reported that this embryonic brain concentration did lead to mitotic arrest. For example, Sager et al. (1984) observed significant increases in mitotic arrests in the cerebellum of mouse pups exposed to Hg on postnatal day 2. The pups were evaluated 24 h after dosing, and concentrations in the cerebella were 1.8 g/g. Decreases in cell numbers were also observed at both 24 h and 19 days after treatment, indicating that the mitotic inhibition by MeHg has long-lasting consequences. Rodier et al. (1984) looked at the effects of MeHg administration to pregnant mice earlier in gestation, on GD 12, with evaluation on GD 13 and GD 14. Embryonic brain Hg levels were 2.3 g/g. They observed significant decreases in the number of late mitotic figures in a unit length of the midbrain ventricular zone 48 h after exposure (decreases at 24 h were noted but were not statistically significant). The mitotic index in midbrains of MeHg-treated animals appeared to be less than those in the controls, although the results were not statistically significant. Surprisingly, the cell number actually increased in the MeHg-treated embryos, with midbrain cell numbers being significantly greater than controls at 48-h postexposure . The authors speculated that this may have represented compensatory growth. While interpretation of the results is complicated, the authors noted that the results support the notion that in utero MeHg exposure arrests cells in mitosis.
Other authors have observed gross malformations (Curle et al., 1987) and behavioral effects (Su and Okita, 1976 ) in mice at embryonic Hg concentrations similar to those observed in our embryonic rats.
A lesser sensitivity of the rat to MeHg developmental effects, as compared to the mouse, has been documented (e.g., Fuyuta et al., 1978) . To a large degree, this differential sensitivity has been attributed to the different toxicokinetics of MeHg in these two species, with the rat sequestering MeHg more avidly in the blood than any other species, thereby lessening the levels distributed to other organs, such as the brain. According to this rationale, it should be possible to produce the same effects in rats and mice if the maternal loading of MeHg was adjusted to produce equivalent organ concentrations. Toxicodynamic differences between the two species, although postulated, have not been demonstrated. The work of Rodier (1995) and Sager (1988) has shown that mice exposed in vivo to MeHg demonstrated cell cycle effects in the developing brain at MeHg levels of 2-3 g/g. Data in the rat are more limited but suggest a higher threshold of sensitivity. For example, Chen et al. (1979) observed that the rate of DNA synthesis in the brains of rat embryos exposed to MeHg in utero were only 36% of the control rat values. The fetal Hg levels in the Chen et al. study were 10 g/g, five times higher than those reported in the mouse studies. Although cell proliferation data in the embryonic rat have not been reported by other authors, other studies with the rat do suggest a lesser sensitivity of the developing rat brain relative to the mouse (e.g., Fredriksson et al., 1993) .
It is unfortunate that we were unable to achieve higher brain concentrations using the acute dosing procedure, because this prevented us from defining the threshold for MeHg's cell cycling effects. Higher concentrations may have been achievable using a multiday dosing regimen (Chen, 1979; Lee and Han, 1995) . The basis for our choice of acute dosing was twofold: Our interest was in performing an in vivo study that would parallel the in vitro study of Ponce et al. (1994) , allowing us to draw a potential in vitro-in vivo comparison. In addition, we were interested in quantifying the effects of MeHg on cell cycle kinetics. Chronic dosing would have complicated the interpretation of our results; if we observed effects on GD 13, it would have been difficult to determine if these were attributable to the tissue burden on GD 13 or to the initial exposures on GD 7. A more invasive approach, such as delivering MeHg directly to the embryos via injection to the uteroplacental circulation, might allow for acute delivery of higher MeHg doses to the embryo, but the effects of the surgery on cell cycle patterns would likely be considerable. Alternatively, whole embryo cultures would allow for more direct control of the dosing, although this would require additional assumptions when drawing conclusions regarding the effects in intact animals.
Our data using colchicine demonstrated that colchicine clearly had a negative impact on the cell cycle. The effects of the colchicine on brain development have been well studied (Kalter, 1968) . The drug blocks dividing cells at metaphase, causing a cessation of cell proliferation (Dalu et al., 1998) . Colchicine has also been shown to decrease BrdU labeling in the brain of developing rats when administered postnatally (Carbajo-Perez and Watanbe, 1990) . The positive results that we obtained using colchicine demonstrate that our analytical method is capable of detecting changes in cell cycling such as might be expected from MeHg treatment.
Using the data in Figure 7 relating in vitro media concentration and intracellular Hg content, we were able to compare in vivo and in vitro studies using a common dose metric of tissue Hg concentration (i.e., g Hg/g cellular material). Figure  8 presents in vivo and in vitro data on the effects of MeHg on cell proliferation. Where applicable, the No Observed Adverse Effect Level (NOAEL), Lowest Observed Effect Level (LOAEL), and highest dose from each study are indicated. The y-axes are mercury concentration in g/g or M in culture media that are aligned and equated using the relationship shown in Figure 7 . As shown in Figure 8 , intraspecies differences in MeHg effects on proliferation in the developing brain are not as noticeable using in vitro systems as they are in vivo. For example, Wasteneys et al. (1988) , using a murine carcinoma cell line, noted effects on microtubule stability at 0.33 M (1 g/g) and decreases in cell growth at 1 M (3 g/g). Similarly, Ponce et al. (1994) , studying rat midbrain cells in vitro, observed decreases in cell cycle progression at 1 M (3 g/g). Similar data may be considered from Miura et al. (1978;  mouse glioma cells), Zucker et al. (1990; mouse leukemia cells) , and Vogel (1985; human fibroblasts) . These in vitro data suggest a quantitative similarity in response to MeHg between species. However, in our in vivo study we observed that, at brain concentrations of approximately 3 g/g, no effects on cell cycling occurred in the rat midbrain. Thus, in vitro systems may not be able to fully quantitatively replicate interspecies differences in isolation and without detailed analyses.
The parallelogram approach has been used to evaluate species differences in chemical sensitivity (Sobels, 1977) . Although used primarily for genotoxicants, the parallelogram may also be useful for evaluating developmental toxicants. Figure 9 illustrates how in vivo and in vitro data for mice, rats, and humans can be used to evaluate cross-species differences in response. The LOAEL values for cell cycle effects in vitro in mice and rats were taken from Figure 8 . For the mouse in vitro LOAEL, we chose the value of 3 g/g from the study of Wasteneys et al. (1988) , while the corresponding rat value of 3 g/g was obtained from the study of Ponce et al. (1994) . The in vivo LOAEL for the mouse was obtained from the study of Sager et al. (1984) . For rats, an LOAEL was interpolated from the study of Chen et al. (1979) , which noted substantial decreases in cell number at 10 g/g; our own data noting an absence of effect at approximately 3 g/g, and the study of Fredrickson et al. (1993) which saw substantial decreases in body weights (presumably a higher dose effect than cell proliferation) at 8 g/g. We therefore estimated that the LOAEL for cell proliferation in the rat would be approximately 4 -6 In this figure open circles represent the no-effects level, while filled circles represent adverse effects. For perspective, brain mercury levels determined at autopsy in "normal" or unsymptomatic human neonates were below 0.3 g/g in a Seychelles population (Lapham et al., 1995) and 0.16 -0.23 g/g in a population in Japan (Nishimura et al., 1974) . Brain mercury levels in two neonates involved in the Minimata poisoning incident ranged from 1 to 13 g/g (Choi et al., 1978) . References: (1) Chen et al. (1979) ; (2) Fredriksson et al. (1993) ; (3) Rodier et al. (1984) ; (4) Sager et al. (1984) ; (5) Ponce et al. (1994) ; (6) Vogel et al. (1985) ; (7) Miura et al. (1978) ; (8) Wasteneys et al. (1988) ; and (9) Zucker et al. (1990) . Note that, where studies involved multiple doses, the NOAEL, LOAEL, and highest dose from the original studies are shown. g/g. In vitro data were not located for human cells. However, human in vivo data collected from neonates in the Minimata episode (Choi et al., 1978) and data from nonsymptomatic neonates (Lapham et al., 1995) suggest a human in vivo LOAEL in the range of 0.5-1.0 g/g. Quantitatively, all of the LOAEL values show a reasonable degree of concordance, spanning approximately an order of magnitude. Comparisons among the in vivo data suggest that humans are at least or more sensitive than the rodent and that mice may be a slightly better model for human developmental neurotoxicity than the rat. The current analysis is based on several assumptions, however, and is limited by differences in study design and comparisons being made across slightly different endpoints (e.g., mitotic index, labeling index, changes in cell number). Additional studies in this narrow dose-response range using consistent designs would be valuable for improving our understanding of species differences in this range of concern. Nonetheless, the parallelogram approach is a useful tool for identifying where detailed assessments are needed to refine our ability to conduct crossspecies comparisons.
Our data provide further information on the effects of MeHg on neurdevelopment and provide cross-species and in vitro to in vivo comparisons. Such comparisons can provide both a quantitative and a qualitative framework for utilizing both in vivo and in vitro data in human health risk assessment. Studies such as this will help to define low-level response to chemical agents and will help to determine how we can use in vitro data to supplement in vivo observations. Dalu, A., Rao, P. S., and Mehendale, H. M. (1998 Wasteneys et al. (1988) and Ponce et al. (1994) , respectively. For the in vitro data, both the culture medium MeHg concentration in M and the predicted tissue concentration in g/g are indicated. The in vivo LOAEL for mice were obtained from Sager et al. (1984) . For rats, an LOAEL was interpolated from Chen et al. (1979) , Fredriksson et al. (1993) , and the current study data (see discussion in text). In vitro data were not located for human neuronal cells. However, human in vivo data collected from neonates in the Minimata episode (Choi et al., 1978) and data from nonsymptomatic neonates (Lapham et al., 1995) suggest a human in vivo LOAEL in the range of 0.5 to 1.0 g/g. Note that the LOAEL values show a reasonable degree of concordance across species, spanning approximately an order of magnitude.
